Representative(s): Johns Assalone TAGRISSO® (osimertinib) Representative john.assalone@astrazeneca.com Frank Schuh IMFINZI® (durvalumab) Representative frank.schuh@astrazeneca.com Peggy Barbola CALQUENCE® (acalabrutinib) Representative peggy.barbola@astrazeneca.com Hayley Larkin LYNPARZA® (olaparib) Representative Hayley.Larkin@astrazeneca.com Kathy Limoni LYNPARZA® (olaparib) Representative Kathryn.Limoni@astrazeneca.com Kim Brier LYNPARZA® (olaparib) Representative kim.brier@astrazeneca.com Barry Eberhardt ADC Franchise Representative barry.eberhardt@astrazeneca.com | AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS. Websites: - Company Website
- IMFINZI® (durvalumab) US HCP Website
- TAGRISSO® (osimertinib) US HCP Website
- CALQUENCE® (acalabrutinib) US HCP Website
- LYNPARZA® (olaparib) US HCP Website
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) US HCP Website - Click to see complete Prescribing Information, including Boxed WARNINGS
| Virtual Exhibit HallMarch 6th, 12:00 - 1:00 p.m. Click here to join the virtual exhibit Meeting ID: 929 5757 3013 Password: 359444 To return to the LIVE educational program 10:40am, click here.
|